BPC-157 20mg

BPC-157 is a synthetic peptide composed of fifteen amino acids. The sequence is derived from a region of a larger gastric protein originally identified in human gastric juice. Researchers studying the protective factors in the stomach in the early 1990s named the parent molecule Body Protection Compound, abbreviated BPC. A 15-residue fragment of this parent protein retained much of the biological activity observed in early experiments, and that fragment is the molecule sold here as BPC-157.

A structural feature worth noting is the unusually high proline content — four proline residues across fifteen amino acids. Proline introduces rigid kinks into peptide backbones, and proline-rich peptides typically show greater resistance to enzymatic degradation than linear peptides of comparable length. Research has reported BPC-157 stability across a wide pH range, including in human gastric juice, consistent with the molecule's gastric origin and the conformational rigidity its sequence imposes.

The compound is supplied as a lyophilized — freeze-dried — white powder in a sealed amber-glass vial under inert gas. Each vial contains 20 mg of peptide. Reconstitution with bacteriostatic water is required before the peptide can be drawn into an insulin syringe. Reconstitution mechanics are covered in the Reconstitution accordion.

BPC-157 has been the subject of an extensive preclinical literature. A 2024 review documented studies across gastric, intestinal, musculoskeletal, vascular, neural, and dermal tissue (PMID 38980576). A 2025 narrative review of musculoskeletal research described both the regenerative findings and the open questions about translation to human clinical use (PMID 40789979). A 2021 review in Frontiers in Pharmacology organised the wound-healing literature by tissue category, covering dermal, tendon, ligament, skeletal-muscle, osseous, peripheral-nerve, and vascular models (PMID 34267654).

Across this body of literature the compound has been described under several names: pentadecapeptide BPC-157, the full Body Protection Compound 157, the early trial designation PL 14736, and the proprietary name Bepecin used in early Croatian pharmaceutical work. These names refer to the same 15-amino-acid sequence. The CAS registry number 137525-51-0 and PubChem CID 9941957 are the canonical chemical identifiers.

No regulatory authority — Health Canada, the FDA, the EMA, the TGA, or any equivalent — has cleared BPC-157 for therapeutic use in humans or animals. Ronin Peptides ships the compound exclusively as a research-grade reagent for benchwork. Dosing protocols, treatment regimens, and administration instructions are out of scope and are not provided in any form.

The most-cited mechanistic finding is that BPC-157 activates the vascular endothelial growth factor receptor 2 (VEGFR2) in vascular endothelial cells (PMID 27847966). VEGFR2 activation triggers downstream Akt phosphorylation and endothelial nitric oxide synthase signaling, raising nitric oxide output and supporting new vessel formation. The Akt-eNOS branch of this cascade is also documented in BPC-157 research focused on the nitric oxide system specifically (PMID 23755725). Nitric oxide release in turn supports vasodilation, which has been proposed as a contributor to the perfusion-related findings in tissue-injury models.

Beyond direct receptor activation, research has reported upregulation of growth hormone receptor expression in tendon fibroblasts following BPC-157 exposure, alongside enhanced cell migration and survival in tissue-repair models (PMID 21030672). Vascular research has documented BPC-157 effects on collateral circulation following major vessel occlusion (PMID 35125818, PMID 23782145), suggesting the compound modulates vascular response under both injury and ischemic conditions. The collateral-pathway findings indicate that BPC-157 may engage existing vasculature rather than relying solely on new vessel formation.

One pharmacokinetic feature shapes how mechanism is interpreted: the gap between plasma clearance and biological persistence. Plasma half-life after parenteral injection in animal models is measured at under thirty minutes. Yet the documented downstream effects on repair, inflammation, and vascular signalling continue for weeks beyond the last dose. Recent reviews favour the interpretation that BPC-157 sets in motion durable transcriptional programs, with continued activity not requiring continued receptor binding (PMID 38675421). Identifying the specific gene-expression changes responsible for this persistence is an open research direction.

Mechanism research remains active. A 2025 patent and literature review catalogued ongoing investigations into Src-caveolin-1 and focal adhesion kinase pathway involvement in tissue migration responses (PMID 40005999). Research on neurotransmitter-system interactions has also been compiled in recent reviews, broadening the picture beyond the classical angiogenic and gastric framings (PMID 38675421).

The largest body of preclinical research on BPC-157 covers tissue-repair models. In rat tendon studies, administration accelerated outgrowth, fibroblast migration, and post-injury cellular survival (PMID 21030672). Skeletal muscle, ligament, and bone-defect models have produced comparable healing-rate findings, summarized in the 2021 wound-healing review (PMID 34267654) and the 2025 musculoskeletal narrative review (PMID 40789979). The repair findings span both acute injury models and surgically induced defect models, suggesting the response is not specific to a single class of tissue insult.

Gastric and intestinal protection is the second major research stream, consistent with the compound's gastric-juice origin. Studies have examined gastric mucosal lesion repair, ulcer models, colitis models, and various inflammatory bowel disease analogues (PMID 17186181, PMID 38980576). The 2006 inflammopharmacology trial designation work introduced PL 14736 as the early-development name for the same compound, with reported activity on gastric vascular response. The 2024 Inflammopharmacology review compiled the most current GI-protection data set across more than two decades of research.

Neuroprotection research includes hippocampal ischemia-reperfusion models in rats (PMID 32558293) and investigations into the brain-gut axis as a candidate explanatory framework for the broad effects observed across tissue types (PMID 27138887). A 2024 review surveyed neurotransmitter-system interactions in this body of work (PMID 38675421), suggesting the compound's effects on central nervous system tissue may share mechanisms with its peripheral activity.

Cardiotoxicity attenuation has been studied in the context of bupivacaine exposure (PMID 27815173), broadening the literature beyond the conventional musculoskeletal and gastric framings. Independent research groups outside the original Sikiric-Seiwerth laboratory have published on the musculoskeletal soft-tissue findings, providing cross-laboratory replication of the core repair-model claims (PMID 30915550). Replication outside the originating group is a meaningful credibility marker in any preclinical literature.

Translation to human clinical application remains limited. The 2025 narrative review noted that despite the volume of preclinical work, well-controlled human trial data are scarce, and the regenerative findings should be interpreted accordingly (PMID 40789979). A 2024 pilot study in interstitial cystitis represents one of few published human-cohort efforts (PMID 39325560), though it is small and single-centre. Researchers planning new work should review the most current literature before designing protocols, with attention to the gap between preclinical breadth and clinical-trial depth.

Every batch is sent to Janoshik Analytical, an independent peptide-analytics laboratory, before any vial reaches the warehouse. Janoshik runs HPLC for purity quantification and runs MS to confirm the molecule's mass against the expected formula; both results plus a per-COA verification key are returned on the Certificate of Analysis. The verification key resolves at janoshik.com to confirm the COA's authenticity.

For privacy and supply-chain protection, Ronin does not publish COAs publicly. To receive the COA for the batch you received, email support@roninpeptides.ca from the email address used at checkout, with your order number. We respond within 24 hours with the COA PDF attached.

Unopened lyophilized vials hold up well under dry ambient storage; usable activity persists for several weeks even without refrigeration. The recommended container is the unopened original vial — keep the seal intact until reconstitution. Refrigeration at 2–8 °C is appropriate once the working timeline extends past a month. A standard freezer at −20 °C handles archival storage; ultra-low storage at −80 °C is rarely needed for typical bench-research timescales.

Keep vials shielded from light, ideally in their original outer packaging. Repeated temperature cycling accelerates degradation noticeably more than steady storage at any single temperature inside the recommended bands — minimise transitions between cold and ambient.

After reconstitution, refrigerate the solution at 2–8 °C without delay. The typical working window for a reconstituted preparation is four to six weeks at fridge temperature. Past that window, peptide concentration drifts downward through chemical degradation pathways even though the bacteriostatic water's benzyl alcohol still suppresses microbial growth. The 0.9% benzyl alcohol holds back bacterial contamination — the dominant spoilage path — but does not arrest the slower hydrolysis, oxidation, and aggregation processes that accumulate in any aqueous peptide solution.

When a research timeline extends past six weeks, common practice is splitting the reconstituted solution into single-use volumes and freezing them at −20 °C immediately. Ice-crystal formation during each freeze-thaw cycle inflicts mechanical damage on peptide chains, and pre-splitting eliminates the cumulative loss that comes from thawing one vial multiple times. Thaw individual aliquots overnight in a refrigerator — never at room temperature — and use them within a few days of thaw.

The reconstituted product should be visually clear and colourless. Discard any vial showing turbidity, suspended particulate, yellowing, or visible precipitate. The diluent of choice is USP-grade bacteriostatic water containing 0.9% benzyl alcohol — see the bacteriostatic water product page for reconstitution-grade water.

BPC-157 and TB-500 are the two most-studied tissue-repair peptides and are often examined together — see the BPC-157 + TB-500 blend for combined-compound research convenience. KPV and GHK-Cu cover overlapping but distinct repair pathways and are typically investigated as standalone compounds.

A 20 mg vial of BPC-157 reconstituted with 3 mL of bacteriostatic water yields a final concentration of approximately 6.67 mg/mL, or 6,667 mcg/mL. Other diluent volumes scale linearly: 2 mL gives 10 mg/mL, 5 mL gives 4 mg/mL.

Reconstitution procedure:

1. Bring both vials — peptide and bacteriostatic water — to room temperature before opening.
2. Sanitise both rubber stoppers with an alcohol swab.
3. Pull the chosen diluent volume into a sterile transfer syringe.
4. Direct the water against the inner wall of the peptide vial as it is injected — never onto the lyophilized cake, since direct impact foams the solution and denatures peptide at the air-water interface.
5. Invert slowly or swirl gently until everything dissolves. Do not vortex; do not shake.
6. Refrigerate at 2–8 °C the moment reconstitution completes.

A finished preparation should be visually transparent with no suspended particulate. If the solution is hazy or contains visible material, treat it as degraded or contaminated and discard.

For dose-volume calculations on insulin syringes, use the Ronin peptide reconstitution calculator. The calculator pre-loads BPC-157 with default reconstitution volumes and converts target doses to U-100 syringe units automatically.

In published preclinical research, BPC-157 has been administered at doses ranging from 6 to 50 micrograms per kilogram body weight in animal models, with most tissue-repair and gastric-protection protocols using 10 to 20 mcg/kg once or twice daily (PMID 21030672, PMID 32558293, PMID 38980576). Routes reported in the literature include intraperitoneal, subcutaneous, intramuscular, intravenous, and oral administration. These figures are research-reference only — Ronin Peptides does not provide dosing recommendations or administration instructions for any non-laboratory purpose.

1. Hsieh MJ et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. PMID: 27847966 | doi:10.1007/s00109-016-1488-y
2. Seiwerth S et al. BPC 157 and blood vessels. Curr Pharm Des. 2014;20(7):1121-1125. PMID: 23782145 | doi:10.2174/13816128113199990421
3. Sikiric P et al. Stable gastric pentadecapeptide BPC 157-NO-system relation. Curr Pharm Des. 2014;20(7):1126-1135. PMID: 23755725 | doi:10.2174/13816128113190990411
4. Chang CH et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780. PMID: 21030672 | doi:10.1152/japplphysiol.00945.2010
5. Zivanovic-Posilovic G et al. Stable gastric pentadecapeptide BPC 157 and bupivacaine. Eur J Pharmacol. 2016;793:56-65. PMID: 27815173 | doi:10.1016/j.ejphar.2016.10.035
6. Sikiric P et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Inflammopharmacology. 2006;14(5-6):214-221. PMID: 17186181 | doi:10.1007/s10787-006-1531-7
7. Sikiric P et al. New studies with stable gastric pentadecapeptide protecting gastrointestinal tract. Inflammopharmacology. 2024;32(5):3119-3161. PMID: 38980576 | doi:10.1007/s10787-024-01499-8
8. Sikiric P et al. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Curr Neuropharmacol. 2016;14(8):857-865. PMID: 27138887 | doi:10.2174/1570159x13666160502153022
9. Vukojević J et al. The effect of pentadecapeptide BPC 157 on hippocampal ischemia/reperfusion injuries in rats. Brain Behav. 2020;10(8):e01726. PMID: 32558293 | doi:10.1002/brb3.1726
10. Gwyer D et al. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159. PMID: 30915550 | doi:10.1007/s00441-019-03016-8
11. Seiwerth S et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Front Pharmacol. 2021;12:627533. PMID: 34267654 | doi:10.3389/fphar.2021.627533
12. Sikiric P et al. The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity. Pharmaceuticals (Basel). 2024;17(4):461. PMID: 38675421 | doi:10.3390/ph17040461
13. Józwiak M et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide — Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2):185. PMID: 40005999 | doi:10.3390/ph18020185
14. McGuire FP et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025;18(12):611-619. PMID: 40789979 | doi:10.1007/s12178-025-09990-7
15. DeFoor MT et al. Injectable Therapeutic Peptides — An Adjunct to Regenerative Medicine and Sports Performance? Arthroscopy. 2025;41(2):150-152. PMID: 39265666 | doi:10.1016/j.arthro.2024.09.005
16. Lee E et al. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med. 2024;30(10):12-17. PMID: 39325560
17. Sikiric P et al. Cytoprotective gastric pentadecapeptide BPC 157 resolves major vessel occlusion disturbances, ischemia-reperfusion injury following Pringle maneuver, and Budd-Chiari syndrome. World J Gastroenterol. 2022;28(1):23-46. PMID: 35125818 | doi:10.3748/wjg.v28.i1.23